Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Long-term safety of Mometasone Furoate administered via a dry powder inhaler in children: Results of an open-label study comparing Mometasone Furoate with Beclomethasone Dipropionate in children with persistent asthma
BMC Pediatrics, 07/14/09
Noonan M et al. - Both MF-DPI doses were well tolerated, with no unusual or unexpected adverse events or safety concerns, and had a similar adverse event profile to that of BDP-MDI 168 micrograms BID.
Related Articles
Clinical importance of identifying immunoglobulin E-mediated disease in patients with Asthma
Clinical Cornerstone, 10/01/09
Relevance Score: 96%
Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma
Osteoporosis International, 10/13/09
Relevance Score: 95%
The Saudi Initiative for asthma
Annals of Thoracic Medicine, 10/13/09
Relevance Score: 95%
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study
Journal of Allergy and Clinical Immunology, 10/09/09
Relevance Score: 95%
Identification of Asthma Phenotypes using Cluster Analysis in the Severe Asthma Research Program
American Journal of Respiratory and Critical Care Medicine, 11/09/09
Relevance Score: 94%
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of Treatment Satisfaction in Children with Allergic Disease Treated with an Antihistamine: An International, Non-Interventional, Retrospective Study
Clinical Drug Investigation, 12/11/09
Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America
Sanofi-aventis, 12/10/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


